GlassScriptPhysician profile
Robert A Edwards
NPI 1750382545
$34,218.88
in general payments reported to CMS, 2019-2025
16 companies · $22K in 2025
The $22K reported for 2025 was more than what 97% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $421 · 2021: $279 · 2022: $303 · 2023: $563 · 2024: $11K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Consulting Fee: $4,463 · Travel and Lodging: $2,901 · Food and Beverage: $2,337 · Education: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,100.00 |
| Consulting Fee | $4,462.50 |
| Travel and Lodging | $2,900.75 |
| Food and Beverage | $2,336.58 |
| Education | $216.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $33,093.16 | 2021-2025 | Venaseal, Closurefast |
| Medtronic Vascular, INC. | $318.54 | 2019-2020 | |
| Intuitive Surgical, INC. | $269.13 | 2020 | |
| Organogenesis INC. | $124.98 | 2023 | Puraply Antimicrobial |
| Smith+Nephew, INC. | $93.61 | 2022-2023 | Renasys Go V2 Home, Pico 7 |
| Abbvie INC. | $77.07 | 2020-2025 | |
| Novo Nordisk INC | $50.19 | 2023 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.66 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $26.32 | 2022 | |
| Abbott Laboratories | $24.20 | 2023 | Freestyle Libre 3 |
| Allergan, INC. | $18.61 | 2022 | |
| Amgen INC. | $17.83 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.71 | 2022 | |
| Glaxosmithkline, LLC. | $15.60 | 2022 | |
| Horizon Therapeutics Plc | $15.19 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.